Here We Go Again: Why is the FDA Reifying Race as Genetic?
By Jonathan Kahn, Biopolitical Times guest contributor
| 03. 17. 2011
In recent years the issue of whether, how and when to use racial categories in biomedicine has been a subject of heated and extended debates that have ranged over wide areas of research and practice. Over the past decade, significant scientific advances sparked by the federally financed Human Genome Project have placed genetics at the center of many of these debates. In no area is this more pronounced than in the field of pharmacogenomics, the study of how individual genetic differences affect drug response.
Ostensibly, pharmacogenomics is all about the individual, not about race. Indeed, part of its promise is its purported ability to move beyond race, to render it irrelevant as a biological category in assessing drugs response. Yet pharmacogenomics remains in its infancy. Some progress has been made, but a
recent report from the Royal Society in the United Kingdom asserts that realizing the promise of truly individualized pharmacogenomic therapies remains decades away. Nonetheless, major government, academia, and industry initiatives are drawing huge amounts of material and intellectual capital into the pursuit of this distant promise.
I am...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...